Lupin Gets US FDA Approval For Oral Suspension, Targets 25% EBITDA Margins

Market snapshot: Lupin has received US FDA approval for Sodium Zirconium Cyclosilicate for Oral Suspension, which serves as a generic equivalent of AstraZeneca's Lokelma® for treating hyperkalemia. The brand recorded estimated annual sales of USD 568 million in the US as of June 2026. This key regulatory milestone comes as management maintains its full-year guidance of high single-digit revenue growth and an EBITDA margin of around 25% for FY27.

Data Snapshot

• Lupin's Q1 FY27 consolidated sales increased by 33.3% year-on-year to ₹8,217.2 crore, compared to ₹6,163.8 crore in Q1 FY26.
• The company's EBITDA margin for Q1 FY27 stood at 31.4%, expanding by 210 basis points year-on-year.
• The reference listed drug Lokelma, bioequivalent to Lupin's new approval, recorded estimated annual sales of USD 568 million in the US.
• Management expects its US business to achieve sales of USD 1.1 billion to USD 1.2 billion in FY27.

What's Changed

• Lupin's Q1 FY27 consolidated sales grew 33.3% year-on-year to ₹8,217.2 crore, up from ₹6,163.8 crore in Q1 FY26, driven by broad-based geographic expansion.
• Gross profit margins reached 74.6% in Q1 FY27 compared to Q1 FY26, supporting EBITDA margin expansion to 31.4% from 29.3% in the prior-year quarter.
• Net debt of the company improved to a negative ₹2,830.8 crore (representing a net cash position) as of June 30, 2026.

Key Takeaways

• Lupin's generic Sodium Zirconium Cyclosilicate targets a sizable USD 568 million US market, cushioning potential revenue losses on other transitioning assets.
• Management is confident in sustaining US revenue above USD 1 billion, guiding for USD 1.1 billion to USD 1.2 billion in FY27 despite growing competition.
• EBITDA margins are guided to stabilize around 25% for the full year FY27, reflecting normalisation from the exceptionally high 31.4% in Q1 FY27.
• US business is expected to pivot back to growth in FY28, supported by 50+ planned launches over the next three years, including 10 exclusive FTFs and 4 biosimilars.

SAHI Perspective

Lupin is systematically building a complex generics and biosimilars engine to replace revenues from its highly profitable, yet increasingly competitive, exclusive assets like Mirabegron and Tolvaptan. While near-term EBITDA margins are guided to adjust downward to 25% from Q1's stellar 31.4%, the target is backed by solid operating leverage and a robust balance sheet. With ₹2,830.8 crore in net cash, Lupin possesses the financial flexibility to fund its intensive R&D program, which remains focused on high-barrier therapeutic areas.

Market Implications

The US FDA approval solidifies Lupin's strong positioning in the US generics space. The addition of complex oral suspensions and upcoming injectables will likely offset pricing erosion in oral solids. For investors, the guided normalisation of EBITDA margins to 25% in FY27 is a known near-term barrier, but the focus shifts to asset execution and facility clearances to ensure the projected FY28 structural recovery remains on track.

Trading Signals

Market Bias: Bullish

The new US FDA approval addresses a USD 568 million market, providing a solid revenue cushion. While near-term EBITDA margins will normalize to 25% in FY27, Lupin's net cash position of ₹2,830.8 crore and a robust complex product pipeline provide strong support for medium-term growth.

Overweight: Pharmaceuticals, Healthcare

Trigger Factors:

• Successful commercial rollout of Sodium Zirconium Cyclosilicate in the US.
• Regulatory clearances of major Indian manufacturing facilities currently under observation.
• Progress of the complex injectable and biosimilar filing pipeline in FY27.

Time Horizon: Medium-term (3-12 months)

Industry Context

Indian pharmaceutical players are transitioning rapidly toward high-barrier complex generics, injectables, and biosimilars to escape the systemic price erosion affecting simple oral solid formulations in the US. Lupin's strategy of committing nearly 70% of its R&D investments toward complex products aligns with this structural industry shift.

Key Risks to Watch

• Accelerated price erosion or stronger-than-expected competition in core products like Tolvaptan and Mirabegron.
• Unexpected regulatory action or compliance delays at key manufacturing plants.
• Execution and launch delays for late-stage biosimilar assets scheduled for FY27 and FY28.

Recent Developments

In Q1 FY27, Lupin achieved record quarterly sales of ₹8,217.2 crore, up 33.3% year-on-year, and consolidated PAT of ₹1,417 crore. The company completed the acquisition of VISUfarma to expand its ophthalmic presence in Europe, and its Nagpur Unit-2 received an EIR from the US FDA.

Closing Insight

Lupin's near-term earnings might see minor volatility as older exclusive products face competition, but its deep pipeline of exclusive first-to-files and complex injectables underpins a robust structural recovery story starting in FY28.

High Performance Trading with SAHI.